Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...
Exelixis (EXEL) Gets a Buy from TD Cowen
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...
Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
MedPage Today3m
Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Stifel maintains hold rating, $30 target on Exelixis stock
Stifel analysts maintained a Hold rating with a $30.00 price target on Exelixis stock (NASDAQ:EXEL), currently trading at $33.32 with a market capitalization of $9.5 billion. According to InvestingPro ...
Park Avenue Securities LLC Makes New $221,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)
Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...
North American Morning Briefing: Stock Futures -2-
Southern Missouri Bancorp Inc (SMBC) is expected to report $1.26 for 2Q. Super Micro Computer Inc (SMCI) is expected to report for 2Q. Transcat Inc (TRNS) is expected to report $0.33 for 3Q. Virginia ...
ENDPOINTS NEWS1h
Bris­tol My­ers shares IO com­bo da­ta in col­orec­tal can­cer; Pfiz­er still wait­ing on Braftovi reg­i­men sur­vival fig­ures
Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded ...